Your one point of contact for Actelion services and support
Ventavis Services & Support

Insurance Coverage Information

Map

PAH Pathways Interactive Resource Locator

PAH Pathways offers a wealth of resources including one-on-one support from PAH Pathways counselors in your area.
Learn more ยป

PAH Pathways counselors understand your patients' concerns when it comes to paying for their therapy. That's why they offer comprehensive and practical information to take some of the hassle out of dealing with reimbursement issues.

PAH Pathways counselors work with your specialty pharmacy to:

  • Verifying insurance
  • Assisting with claims appeals
  • Clarifying patients' co-payment amount before their prescription is filled
  • Offering information about financial assistance for patients who are uninsured or who need help paying for their medication

Financial Assistance Programs

When your patients need help paying for Ventavis

There are a number of financial assistance programs—sponsored both by PAH Pathways and other sources—that may help eligible Ventavis patients pay for their therapy:

  • Ventavis Patient Assistance Program (VPAP) may provide therapy at no cost to eligible patients
  • Caring Voice Coalition (CVC)* offers a PAH co-pay assistance program for eligible patients
    • CVC may also provide assistance with insurance policy premiums, emergency financial needs, and peer support groups
    • Contact CVC at 1-888-267-1440 or visit www.caringvoice.org

*Caring Voice Coalition is a nonprofit, independent third-party organization.
Ineligible patients: Any patients whose prescriptions are paid for by the government, Medicare, Medicaid, VA/DOD (Tricare), or Indian Health Service, patients in Massachusetts and Puerto Rico, or where prohibited by law.

Ventavis is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms.

Important safety information about Ventavis:

In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. Ventavis should not be initiated in patients with systolic blood pressure less than 85 mm Hg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.

Please see full Prescribing Information

Tracleer

Please see full Prescribing Information, including BOXED WARNING and Medication Guide for Tracleer.